NASDAQ:GRFS - Grifols Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$18.06
▲ +0.23 (1.29%)

This chart shows the closing price for GRFS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Grifols Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRFS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRFS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Grifols in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $18.06.

This chart shows the closing price for GRFS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Grifols. This rating has held steady since September 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/14/2021Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyMedium
4/27/2021Berenberg BankReiterated RatingBuyMedium
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageHoldLow
3/23/2021Credit Suisse GroupUpgradeNeutral ➝ OutperformHigh
3/11/2021HSBCUpgradeHold ➝ BuyHigh
3/10/2021Morgan StanleyReiterated RatingOverweightHigh
3/2/2021Credit Suisse GroupReiterated RatingNeutralLow
3/2/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
2/12/2021Berenberg BankReiterated RatingBuyLow
1/22/2021BarclaysReiterated RatingOverweightLow
1/20/2021Credit Suisse GroupReiterated RatingNeutralLow
1/13/2021Morgan StanleyReiterated RatingOverweightLow
12/9/2020Morgan StanleyReiterated RatingOverweightLow
11/6/2020Morgan StanleyReiterated RatingOverweightLow
10/30/2020Berenberg BankReiterated RatingBuyLow
10/1/2020CitigroupUpgradeSell ➝ NeutralLow
9/30/2020Morgan StanleyReiterated RatingOverweightLow
7/21/2020Berenberg BankReiterated RatingBuyLow
6/23/2020Morgan StanleyReiterated RatingOverweightLow
6/10/2020Berenberg BankReiterated RatingBuyMedium
6/9/2020CitigroupDowngradeNeutral ➝ SellMedium
6/9/2020HSBCUpgradeReduce ➝ HoldMedium
6/1/2020BarclaysReiterated RatingOverweightLow
4/21/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
3/27/2020Kepler Capital MarketsReiterated RatingHoldMedium
3/25/2020CitigroupDowngradeBuy ➝ NeutralLow
3/6/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
3/1/2020Kepler Capital MarketsReiterated RatingHoldHigh
12/12/2019William BlairReiterated RatingOutperformLow
12/9/2019Banco SabadellUpgradeSell ➝ BuyMedium
10/30/2019Berenberg BankUpgradeBuyLow
10/28/2019SantanderUpgradeHold ➝ BuyLow
6/27/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$21.00 ➝ $22.50High
2/8/2019Berenberg BankDowngradeBuy ➝ HoldHigh
1/2/2019Morgan StanleyLower Price TargetUnderweight ➝ Underweight$20.00 ➝ $19.00Low
10/30/2018SantanderUpgradeUnderperform ➝ HoldLow
10/11/2018Berenberg BankUpgradeHold ➝ BuyMedium
10/3/2018UBS GroupDowngradeNeutral ➝ SellHigh
10/1/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$22.00 ➝ $20.00Low
6/13/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
6/1/2018BarclaysInitiated CoverageOverweightMedium
3/14/2018HSBCUpgradeReduce ➝ HoldLow
3/1/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$23.00 ➝ $22.00Medium
11/24/2017UBS GroupDowngradeOutperform ➝ Market PerformN/A
10/31/2017CitigroupInitiated CoverageBuy ➝ BuyN/A
7/4/2017Bank of AmericaReiterated RatingBuyMedium
6/30/2017The Goldman Sachs GroupDowngradeBuy ➝ NeutralLow
4/6/2017Bank of AmericaInitiated CoverageBuy ➝ BuyLow
3/30/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightHigh
2/27/2017The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyN/A
1/3/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightN/A
12/13/2016UBS GroupDowngradeBuy ➝ NeutralN/A
(Data available from 6/21/2016 forward)
Grifols logo
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Read More

Today's Range

Now: $18.06
Low: $17.67
High: $18.12

50 Day Range

MA: $18.03
Low: $16.76
High: $18.94

52 Week Range

Now: $18.06
Low: $14.81
High: $20.60

Volume

23,209 shs

Average Volume

802,092 shs

Market Capitalization

$12.42 billion

P/E Ratio

18.81

Dividend Yield

0.11%

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Grifols?

The following Wall Street sell-side analysts have issued stock ratings on Grifols in the last twelve months: Barclays PLC, Berenberg Bank, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, JPMorgan Chase & Co., Morgan Stanley, and Zacks Investment Research.
View the latest analyst ratings for GRFS.

What is the current price target for Grifols?

0 Wall Street analysts have set twelve-month price targets for Grifols in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Grifols in the next year.
View the latest price targets for GRFS.

What is the current consensus analyst rating for Grifols?

Grifols currently has 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GRFS will outperform the market and that investors should add to their positions of Grifols.
View the latest ratings for GRFS.

What other companies compete with Grifols?

How do I contact Grifols' investor relations team?

Grifols' physical mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company's listed phone number is (493) 571-2200 and its investor relations email address is [email protected] The official website for Grifols is www.grifols.com.